Interactions between Effectors Linked to Serotonin Receptors

ABSTRACT: In general, there are two types of interactions between effector signaling pathways. “Homologous” interactions are those that occur within a receptor system to alter its own responsiveness, for example the loss of responsiveness (desensitization) that can occur upon agonist occupancy of a receptor. “Heterologous” interactions are those that occur between different receptor systems where the responsiveness of one receptor system is regulated (positively or negatively) by activation of another receptor system (i.e., “cross‐talk”). Many, if not all receptors, couple to multiple cellular effector pathways and alterations in the responsiveness of a receptor system can be effector pathway‐dependent which underscores the importance of studying each effector coupled to a receptor. Regulation of receptor system responsiveness, and consequently the efficacy of drugs, is a highly dynamic process. Perhaps by exploiting these interactions, new targets for pharmacotherapy may be uncovered which will provide for increased efficacy and specificity of drug action.

[1]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[2]  P. Leff,et al.  A three-state receptor model of agonist action. , 1997, Trends in pharmacological sciences.

[3]  G. Milligan,et al.  Up‐regulation of a constitutively active form of the β 2‐adrenoceptor by sustained treatment with inverse agonists but not antagonists , 1996, FEBS letters.

[4]  G. Milligan,et al.  Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. , 1996, Molecular pharmacology.

[5]  S. Maayani,et al.  5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. , 1996, Molecular pharmacology.

[6]  G. Martin,et al.  Characterization of a 5‐HT1B receptor on CHO cells: functional responses in the absence of radioligand binding , 1996, British journal of pharmacology.

[7]  I. Forbes,et al.  In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British Journal of Pharmacology.

[8]  S. Siegelbaum,et al.  Hippocampal long-term depression: Arachidonic acid as a potential retrograde messenger , 1995, Neuropharmacology.

[9]  M. Kaufman,et al.  Serotonin 5‐HT2C Receptor Stimulates Cyclic GMP Formation in Choroid Plexus , 1995, Journal of neurochemistry.

[10]  A. Saltzman,et al.  Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. , 1994, Molecular pharmacology.

[11]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[12]  R. McKay,et al.  5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms. , 1994, Molecular pharmacology.

[13]  E. sanders-Bush,et al.  5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. , 1993, Molecular pharmacology.

[14]  B. Hoffman,et al.  Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. , 1992, Molecular pharmacology.

[15]  M. Kaufman,et al.  The 5‐HT1C Receptor , 1990, Annals of the New York Academy of Sciences.

[16]  Takao Shimizu,et al.  Arachidonic Acid Cascade and Signal Transduction , 1990, Journal of neurochemistry.

[17]  S. Svebak,et al.  Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. , 1990, The Journal of clinical psychiatry.

[18]  J. Axelrod,et al.  Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Murphy,et al.  Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids. , 1988, Pharmacological reviews.

[20]  P. Conn,et al.  A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Conn,et al.  Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. , 1985, The Journal of pharmacology and experimental therapeutics.